99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy
- 1 May 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 24 (5), 537-542
- https://doi.org/10.1097/00006231-200305000-00009
Abstract
Technetium-99m 2-methoxyisobutylisonitrile (99mTc-MIBI) is a lipophilic agent that has been proposed as a useful tracer for the detection of disease sites in patients with multiple myeloma (MM). We performed a prospective study to determine the potential of 99mTc-MIBI imaging for the evaluation of the extent of primary disease in patients with advanced stage MM, compared with skeletal survey and bone scintigraphy. Twenty patients with advanced stage MM at initial diagnosis underwent whole-body 99mTc-MIBI imaging, together with contemporaneous skeletal survey and bone scintigraphy. The findings of 99mTc-MIBI imaging were correlated with the results of skeletal survey and bone scan. All 99mTc-MIBI scans were positive for the presence of active MM, whereas skeletal surveys were positive in 18 patients (90%) with osteolytic lesions. Bone scintigraphy demonstrated MM in only 15 patients (75%). In two patients with no detectable lesions on skeletal survey, 99mTc-MIBI imaging revealed uptake in the spine, corresponding to the abnormalities seen on magnetic resonance imaging (MRI). With respect to the localization of bone lesions, 99mTc-MIBI imaging was superior to bone scintigraphy in 15 patients (75%) and had concordant results with bone scintigraphy in four (20%). 99mTc-MIBI imaging is a very sensitive imaging modality for the identification of the extent of disease in patients with advanced MM. It is clearly superior to bone scintigraphy and complements the results of skeletal survey by finding additional disease sites. Hence, in active MM patients, 99mTc-MIBI imaging has the potential to detect bone marrow disease that cannot be detected by skeletal survey and bone scintigraphy.Keywords
This publication has 11 references indexed in Scilit:
- Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonateAnnals of Hematology, 2001
- Bone marrow uptake of 99mTc-MIBI in patients with multiple myelomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Tc-99m MIBI Localization in Bone Marrow: A Marker of Bone Marrow MalignancyClinical Nuclear Medicine, 1998
- Different patterns of technetium-99m sestamibi uptake in multiple myelomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.Journal of Clinical Oncology, 1998
- In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- The use of 99mTc-MIBI scanning in multiple myelomaBritish Journal of Cancer, 1996
- Radiography and bone scintigraphy in multiple myeloma; a comparative analysisThe British Journal of Radiology, 1982
- Comparison of bone scintigraphy and radiography in multiple myeloma.Radiology, 1980
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975